On September 17, the intersection of AI and life sciences once again became a focal point for capital markets as Hong Kong stocks closed with METIS TECHBIO-P (07666) rising 12.70% and INSILICO (03696) up 6.86%. During US trading hours, Tempus AI (TEM.US) hit an intraday high of $81.12, a gain of 15.93%, while DIAGENS-B (02526) closed up just 0.39% on the same day.

While daily fluctuations cannot encapsulate a company's true worth, they offer a compelling observation window: as the market begins to assign higher valuations to medical data, scientific workflows, and AI platforms, is the capability set that DIAGENS-B is building still being undervalued?

Tempus's operational metrics provide some clues. In its fiscal 2026 second quarter, the company's data and applications business generated $93.2 million in revenue, up 28% year-over-year, with Insights-related operations growing 36%. New licensing agreements signed during the quarter totaled approximately $200 million, though this figure represents contracted value rather than fully recognized revenue for the period.

At the Morgan Stanley Global Healthcare Conference on September 15, Tempus management emphasized that its competitive moat stems from hospital connections, compliance protocols, data pipelines, and the alignment of clinical records with molecular, pathology, and imaging information. The company subsequently announced plans to construct a platform containing 100,000 whole genomes linked to longitudinal clinical data over the coming years, with ambitions to eventually scale to 1 million.

The market's attention is shifting from individual AI products toward systems capable of continuously producing high-quality medical data and model capabilities—precisely the core tenet of AI4S (AI for Science). Industry-standard definitions describe AI4S as connecting machine learning with scientific data, mechanistic knowledge, simulation computing, and experimental validation to enhance hypothesis generation, prediction, and knowledge discovery efficiency. AlphaFold 3 unifies predictions across multiple classes of biomolecular interactions, while GNoME demonstrates a pathway from candidate discovery to stability assessment; China's "AI+" initiative likewise identifies AI-augmented scientific research as a priority direction.

AI4S ultimately depends on repeatable validation and continuous iteration, making data quality, expert knowledge, and feedback loops foundational infrastructure. Following this line of analysis, DIAGENS-B emerges as a company more closely aligned with the essence of AI4S. It organizes real medical problems, imaging data, expert judgment, model training, evaluation, and application feedback into a single production pipeline. Its iMedLoop platform, launched on July 4, 2026, integrates data ingestion, professional annotation, review and quality control, training and evaluation, deployment, and application feedback; iMedStudio supports AI pre-annotation, expert revision, multi-user result comparison, and dispute arbitration, with related functions already deployed in clinical research and internal R&D projects.

This workflow transforms tacit knowledge from medical practice into auditable, trainable, and reusable data and model development capabilities. Models assist experts with materials; experts correct model errors; within authorized boundaries, quality-controlled data enters training and validation cycles. When facing false positives or edge cases, the platform can design targeted samples and use independent testing within projects to measure improvement. Each real-world task has the opportunity to accumulate task definitions, data standards, quality control rules, and deployment experience.

As of the evening of September 17, the iMedLoop website displayed approximately 29.015 million annotated samples, 466.8 TB of imaging data, 222 active tasks, and 3,172 certified experts. The user agreement stipulates that uploaded data does not transfer intellectual property rights, with usage and benefits governed by specific authorizations; the current free-credit experience model will transition to publicly disclosed paid services at a later date.

The core competitiveness of DIAGENS-B lies in organizing, governing, and transforming data, providing a foundation for long-term collaboration with hospitals, experts, and research institutions. The company already exhibits an observable commercial base. In the first half of 2026, model service revenue reached RMB 94.541 million, up 101.1% year-over-year, representing 86.9% of total revenue. Since iMedLoop launched in July, after the reporting period, the platform's impact will be measured by whether model iteration drives increased usage and payment, whether data and tools reduce development and delivery costs, and whether the same platform can be reused across multiple specialties.

These three pathways correspond to revenue growth, cost optimization, and business expansion—together constituting the most imaginative aspects of DIAGENS-B. As tasks accumulate, the platform may codify methods for continuously improving models; as methods are reused, the time from new problem to usable tool may shorten, and collaboration efficiency across the data and expert network may improve.

DIAGENS-B is constructing the "problem identification—data organization—model training—validation—redeployment" loop that AI4S prizes. Expert feedback, incremental data, and retraining alone cannot demonstrate autonomous recursive self-improvement, nor do they replace independent testing and deployment monitoring. Evidence supporting a valuation re-rating will come from model iteration results, licensing partnerships, sustained payment behavior, and cost efficiency.

Tempus's rally reminds the market that high-quality medical data, when integrated into real workflows and generating commercial returns, merits higher pricing. What deserves a fresh look at DIAGENS-B is precisely the next-generation model production system being built beyond its current product offerings. For investors seeking AI4S candidates that sit close enough to scientific problems while retaining platform-scale optionality, public disclosures suggest DIAGENS-B possesses the key conditions to be among the most pure-play and imaginative targets. Its "purity" derives from AI directly applied to medical research tasks; its "imagination" stems from every real-world task potentially serving as the starting point for the next round of model capability and commercial efficiency.